Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes

Aludwan, Mahmoud; Kobyliak, Nazarii; Abenavoli, Ludovico; Kononenko, Liudmyla; Shuliarenko, Larysa; Kyriienko, Dmytro; Komisarenko, Iuliia

doi:10.5603/dk.2020.0036

Cited by 6 publications

(1 citation statement)

References 41 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, there was a predominance of female gender which could be contributed to the fact that vitamin ‘D’ deficiency is more common among females; due to several factors such as It is related to several factors such as dietary habits insufficient dietary calcium, obesity, and traditional clothing by covering most of the body and restricted out-door activities (lack of sun exposure due to cultural and social factors) which agrees with previous studies [28,29].…”

Section: Discussionsupporting

confidence: 91%

Steatosis regression assessed by cap after Vitamin ‘D’ supplementation in NAFLD patients with Vitamin ‘D’ deficiency

Emam,

Soliman,

Darweesh

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and previous studies suggested a relationship between vitamin D deficiency and NAFLD. It is suggested that vitamin D supplementation may have significant beneficial effect on liver biochemistry and histology. Objective This study aims to assess the degree of possible steatosis regression using controlled attenuation parameter (CAP) in NAFLD patients with vitamin D deficiency after vitamin D supplementation and evaluating its effect on lipid profile and transaminases. Patients and methods This study was conducted on 100 NAFLD patients with vitamin D deficiency. They received 10000 IU/week of vitamin D orally for 3 months. CAP was used to assess hepatic steatosis and fibrosis before/after intervention. Transaminases, lipid profile, and vitamin D levels were evaluated before/after treatment. Results Serum AST, ALT, cholesterol, TG, LDL and HDL showed a significant reduction posttreatment in patients with both normal and elevated baseline levels (P < 0.001). The posttreatment mean CAP showed a significant reduction (300.44 ± 37.56 vs. 265 ± 36.19 dB/ml) (P < 0.001), and there was a significant improvement in the mean fibrosis values by LSM (5.32 ± 1.53 vs. 4.86 ± 1.28 KPa) (P = 0.001). After supplementation, serum vitamin D level was raised significantly in the majority of patients (P < 0.001); however, only 13% of them reached sufficient levels (>30 ng/ml), insufficient levels (20–29 ng/ml) was reached in 83% and 5% showed vitamin D deficiency (<20 ng/ml). Conclusion A significant improvement was detected in hepatic steatosis (by CAP); mean values of LSM, transaminases and lipid profile after three months of oral vitamin D supplementation.

show abstract

Section: Discussionsupporting

confidence: 91%

Steatosis regression assessed by cap after Vitamin ‘D’ supplementation in NAFLD patients with Vitamin ‘D’ deficiency

Emam,

Soliman,

Darweesh

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3

Pastukhova

Luzza

Shevel

et al. 2022

RRCT

View full text Add to dashboard Cite

Background: Type 2 diabetes is a metabolic disease characterized by hyperglycemia on the background of insulin resistance and decreased insulin secretion. A relatively large number of patients with this type of diabetes have abdominal obesity, which also affects insulin resistance development. Chronic hyperglycemia can lead to damage and dysfunction of various organs, and a striking example is diabetic nephropathy. Diabetic nephropathy is a specific kidney damage that occurs due to complications of diabetes and is accompanied by the formation of diffuse or nodular glomerulosclerosis, which can lead to terminal renal failure and requires the immediate substitution of renal therapy or renal transplantation. Diabetic nephropathy is diagnosed with albuminuria and a decrease in the rate of glomerular filtration. Methods: This review was based on a literature search for the most important evidence on the issue of considering vitamin D as a possible method of prevention of obesity, type 2 diabetes, and diabetic nephropathy. Collected published articles were summarized according to their overall themes Results: In this review, we considered vitamin D as a possible method of treatment of type 2 diabetes, as well as its complications - diabetic nephropathy. Conclusion: Studies show that vitamin D inhibits the renin-angiotensin-aldosterone system, resulting in improved renal function in diabetic nephropathy. Vitamin D also has the anti-inflammatory, antiproliferative, and anti-metastatic effect, which improves endothelial function.

show abstract

Оценка Клинической Эффективности Заместительной Терапии Препаратом Декап У Пациентов С Сахарным Диабетом Типа 2 И Сопутствующей Неалкогольной Жировой Болезнью Печени При Дефиците Витамина D

Aludwan¹,

Kobyliak²,

Павленко³

et al. 2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Background. Recently, vitamin D deficiency has been considered one of the factors in the development of type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD). The purpose was to establish the effectiveness of Decap (cholecalciferol) in patients with its deficiency who suffered from type 2 DM and NAFLD. Materials and methods. Fifty-two people with NAFLD and type 2 DM on the background of established D-deficiency were treated, they were evenly divided into two groups. Patients in the comparison group (n = 26) received only traditional antidiabetic therapy, and the main group (n = 26) additionally took vitamin D — Decap, which was prescribed at a dose of 4,000 IU/day for 6 months. Results. Vitamin D use was associated with a statistically significant reduction in fasting blood glucose after 6 months of treatment — by 4.2 % (p = 0.041). The level of glycated hemoglobin in the main group of patients decreased on average by 0.38 % (p = 0.121) after 3 months, and remained almost at the same level after 6 months — by 0.44 % (p = 0.088). In parallel with the improvement of glycemic control parameters in the main group, there was a tendency to a decrease in the HOMA-2-IR by 0.28 (–0.11; 0.86; p = 0.152) and to a better insulin sensitivity by 1.39 (–10.04; 6.01; p = 0.621) compared to the baseline. The use of vitamin D (Decap) is associated with a decrease in steatosis indices FLI and TyG. The baseline values for FLI was 74.11 ± 18.71 and for TyG — 5.21 ± 0.29, and after a six-month course of vitamin D treatment, they decreased by 4.4 % (p = 0.029) and 2.68 % (p = 0.031), respectively, compared to baseline. Conclusions. It was found that the use of Decap in patients with vitamin D deficiency at a dose of 4,000 IU/day for a course of at least six months improved glycemic control and metabolic profile in those with type 2 DM and NAFLD.

show abstract

Hepatic steatosis indices as predictors of vitamin D3 deficiency in patients with NAFLD associated with type 2 diabetes

Cited by 6 publications

References 41 publications

Steatosis regression assessed by cap after Vitamin ‘D’ supplementation in NAFLD patients with Vitamin ‘D’ deficiency

Steatosis regression assessed by cap after Vitamin ‘D’ supplementation in NAFLD patients with Vitamin ‘D’ deficiency

Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3

Contact Info

Product

Resources

About